Felicitex Therapeutics Inc. (FLCT)

Felicitex Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 44.73M
Revenue (ttm) n/a
Net Income (ttm) -1.97M
Shares Out 7.16M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About FLCT

Felicitex Therapeutics is a preclinical oncology drug development company focused on developing therapies targeting dormant and active cancer cells. We have designed and patented small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired resistance mechanisms. Our drug candidates are intended to be effective acr... [Read more]

Industry Health Care
Sector Pharmaceuticals
Founded 2012
Employees 2
Stock Exchange NASDAQ
Ticker Symbol FLCT
Full Company Profile

Financial Performance

Financial Statements


Felicitex Therapeutics IPO Registration Document (S-1)

Felicitex Therapeutics has filed to go public with an IPO on the NASDAQ.

2 years ago - SEC